| Item |
Information |
|
Drug Groups
|
illicit; approved |
|
Description
|
Drostanolone (also known as dromostanolone) is a potent synthetic androgenic anabolic steroid similar to testosterone. Drostanolone is indicated in postmenopausal women with recurrent breast cancer, in a combined hormone therapy. |
| Indication |
For use in females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal. |
| Pharmacology |
Dromostanolone is a synthetic androgen, or male hormone, similar to testosterone. Dromostanolone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells. |
| Toxicity |
Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Absorption |
Well absorbed following parenteral administration. |
| External Links |
|